Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

NCT05569187 ·Status: COMPLETED

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

NCT03839823 ·Status: COMPLETED ·Phase: PHASE2

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

NCT03439046 ·Status: COMPLETED ·Phase: PHASE3

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

NCT00334802 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

NCT06075758 ·Status: COMPLETED

A Study of LY3007113 in Participants With Advanced Cancer

NCT01463631 ·Status: COMPLETED ·Phase: PHASE1

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146 ·Status: ACTIVE_NOT_RECRUITING

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836 ·Status: COMPLETED ·Phase: PHASE1

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT03096847 ·Status: COMPLETED ·Phase: PHASE3

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

NCT03477396 ·Status: COMPLETED ·Phase: PHASE2

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

NCT02058381 ·Status: COMPLETED ·Phase: PHASE1

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

NCT03081234 ·Status: WITHDRAWN ·Phase: PHASE3

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751 ·Status: COMPLETED ·Phase: PHASE2

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

NCT03538171 ·Status: UNKNOWN ·Phase: PHASE3

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949 ·Status: COMPLETED ·Phase: PHASE1

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

NCT05814354 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

NCT03084939 ·Status: COMPLETED ·Phase: PHASE3

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00030537 ·Status: COMPLETED ·Phase: PHASE2

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225 ·Status: COMPLETED ·Phase: PHASE1

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

NCT06905301 ·Status: RECRUITING

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

NCT06656624 ·Status: RECRUITING ·Phase: PHASE2

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

NCT04055493 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3